Structure Therapeutics Inc. announced positive topline data from the ACCESS clinical program of aleniglipron for the treatment of obesity and overweight with related co-morbidities.
Aleniglipron demonstrated significant weight loss and tolerability in Phase 2b ACCESS study and ongoing ACCESS II study.
The data support the advancement of aleniglipron into Phase 3 clinical development, showcasing its potential in addressing metabolic diseases.
Mean Weight Loss
Placebo-adjusted weight loss of 11.3% (27.3 lbs) observed with 120 mg dose in Phase 2b ACCESS study.
Dose-Dependent Results
Higher dose of 240 mg led to up to 15.3% (35.5 lbs) weight loss in ACCESS II study.
Safety Profile
Aleniglipron showcased a favorable safety and tolerability profile, supporting its future use.
Phase 3 Advancement
Positive findings in the studies pave the way for aleniglipron's progression into Phase 3 clinical development.
- The weight loss data from aleniglipron studies show promising results without evidence of a weight loss plateau by Week 36.
- Aleniglipron's differentiated weight loss and safety profile indicate its potential as an accessible therapy for obesity treatment globally.
The positive topline data from the ACCESS program highlight the success of aleniglipron in addressing obesity and related conditions, with a clear path towards Phase 3 development. Structure Therapeutics is poised to make significant advancements in metabolic disease treatment.